Top

Diabetology & Metabolic Syndrome

Published in:

Open Access 01-12-2018 | Research

The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan

Authors: Nahla Khawaja, Jawad Abu-Shennar, Mohammed Saleh, Said S. Dahbour, Yousef S. Khader, Kamel M. Ajlouni

Published in: Diabetology & Metabolic Syndrome | Issue 1/2018

Abstract

Background

Peripheral neuropathy is one of the most common microvascular complication of diabetes mellitus. This study is conducted to determine the prevalence of diabetic peripheral neuropathy (DPN) and its associated factors among patients with type 2 diabetes mellitus in Jordan.

Methods

A cross-sectional study was conducted at the National Center for Diabetes, Endocrinology and Genetics, Jordan. A total of 1003 patients with type 2 diabetes were recruited. Data were collected from participants during a face-to-face structured interview. DPN was assessed using the translated version of Michigan Neuropathy Screening Instrument (MNSI).

Results

The overall prevalence of DPN based on MNSI was 39.5%. The most frequently reported symptoms were numbness (32.3%) and pain with walking (29.7%), while the least reported symptoms were the history of amputation (1.3%) and loss of sensation in legs/feet while walking (3.8%). Logistic regression analysis revealed that unemployment, cardiovascular disease, dyslipidemia, diabetic retinopathy and long standing DM (diabetes of ≥ 5 years) were significantly associated with DPN.

Conclusion

Peripheral Neuropathy is highly prevalent among Jordanian patients with type 2 diabetes mellitus. DPN was significantly associated with duration of DM, dyslipidemia, diabetic retinopathy, cardiovascular disease, and unemployment. Early detection and appropriate intervention are mandatory among high-risk groups.

International Diabetes Federation (IDF) 2017. IDF Diabetes Atlas 8th ed. http://www.diabetesatlas.org/resources/2017-atlas.html. Accessed 22 Jan 2018.

Ajlouni K, Khader YS, Batieha A, Ajlouni H, El-Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complicat. 2008;22:317–24. https://doi.org/10.1016/j.jdiacomp.2007.01.004.CrossRefPubMed

Khader Y, Batieha A, Ajlouni H, El-Khateeb M, Ajlouni K. Obesity in Jordan: prevalence, associated factors, comorbidities, and change in prevalence over ten years. Metab Syndr Relat Disord. 2008;6(2):113–20. https://doi.org/10.1089/met.2007.0030.CrossRefPubMed

World Health Organization. http://www.who.int/topics/obesity/en/. Accessed 22 Jan 2018.

Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8–14. https://doi.org/10.1002/dmrr.2239.CrossRefPubMed

Callaghan BC, Cheng HT, Stables CL, Andrea L, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34. https://doi.org/10.1016/s1474-4422(12)70065-0.CrossRefPubMedPubMedCentral

Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diabetes Rep. 2012;12:376–83. https://doi.org/10.1007/s11892-012-0278-3.CrossRef

Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998;15:508–514. https://doi.org/10.1002/(SICI)1096-9136(199806)15:6<508::AID-DIA613>3.0.CO;2-L.

Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag. 2007;3:65–76.PubMedPubMedCentral

10.

Boulton AJ, Vinik AI, Arezzo JC, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–62. https://doi.org/10.2337/diacare.28.4.956.CrossRefPubMed

11.

Palumbo PJ, Melton LJ. Peripheral vascular disease and diabetes. Diabetes Am. 1995;2:401–8.

12.

Rathur HM, Boulton AJ. The diabetic foot. Clin Dermatol. 2007;25:109–20. https://doi.org/10.1016/j.clindermatol.2006.09.015.CrossRefPubMed

13.

Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB. Diabetes, vestibular dysfunction, and falls: analyses from the National Health and Nutrition Examination Survey. Otol Neurotol. 2010;31:1445–50. https://doi.org/10.1097/mao.0b013e3181f2f035.CrossRefPubMed

14.

Niranjan Y, Santwani MA, Baghel MS. Quality of life consequences in diabetic polyneuropathy. Glob J Res Med Plants Indig Med. 2012;1:295–300.

15.

Jordan statistical yearbook 2016. Department of Statistics.

16.

American Diabetes Association. Standards of medical care in diabetes. Diabetes care. 2014;37(Supp1):S14–80. https://doi.org/10.2337/dc14-s014.CrossRef

17.

Scale DE. Michigan Diabetes Research and Training Center. Online. https://diabetesresearch.med.umich.edu/Tools_SurveyInstruments.php. Accessed 22 Jan 2018.

18.

Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, Feldman EL. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabetes Med. 2012;29:937–44. https://doi.org/10.1111/j.1464-5491.2012.03644.x.CrossRef

19.

Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108:477–81. https://doi.org/10.1016/j.clineuro.2005.08.003.CrossRefPubMed

20.

Al-Geffari M. Comparison of different screening tests for diagnosis of diabetic peripheral neuropathy in Primary Health Care setting. Int J Health Sci. 2012;6:127–34. https://doi.org/10.12816/0005988.CrossRef

21.

Tabatabaei-Malazy O, Mohajeri-Tehrani MR, Madani SP, Heshmat R, Larijani B. The prevalence of diabetic peripheral neuropathy and related factors. Iran J Public Health. 2011;40:55–62. https://doi.org/10.1097/qad.0b013e328345889d.PubMedPubMedCentralCrossRef

22.

Al-Kaabi JM, Al-Maskari F, Zoubeidi T, Abdulle A, Shah SM, Cragg P, Afandi B, Souid A. Prevalence and determinants of peripheral neuropathy in patients with type 2 diabetes attending a tertiary care center in the United Arab Emirates. J Diabetes Metab. 2014;5:346–53. https://doi.org/10.4172/2155-6156.1000346.CrossRef

23.

Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig. 2014;5:714–21. https://doi.org/10.1111/jdi.12223.CrossRefPubMedPubMedCentral

24.

Elrefai JM. Prevalence of neuropathy in the diabetic foot. Neurosciences. 2009;14:163–6.PubMed

25.

Al-Sarihin K, Althwabia I, Khaled MB, Haddad F. Prevalence of peripheral neuropathy among patients with diabetes mellitus at King Hussein Hospital, Amman, Jordan. RMJ. 2013;38:92–6.

26.

Pop-Busui R, Lu J, Lopes N, Jones TL. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D Cohort. J Peripher Nerv Syst. 2009;14:1–3. https://doi.org/10.1111/j.1529-8027.2009.00200.x.CrossRefPubMedPubMedCentral

27.

Liu F, Bao Y, Hu R, Zhang X, Li H, Zhu D, Li Y, Yan L, Li Y, Lu J, Li Q, Zhao Z, Ji Q, Jia W. Screening and prevalence of peripheral neuropathy in type 2 diabetic outpatients: a randomized multicenter survey in 12 city hospitals of China. Diabetes Metab Res Rev. 2010;26:481–9. https://doi.org/10.1002/dmrr.1107.CrossRefPubMed

28.

Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr. 2012;4:21–8. https://doi.org/10.1186/1758-5996-4-21.CrossRefPubMedPubMedCentral

29.

Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, Cha BY. Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea. Diabet Med. 2012;29:e290–6. https://doi.org/10.1111/j.1464-5491.2012.03697.x.CrossRefPubMed

30.

Rosson GD, Dellon AL. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:1925–7. https://doi.org/10.1056/nejmoa032782.CrossRefPubMed

31.

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70. https://doi.org/10.2337/dc06-1216.CrossRefPubMed

32.

Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH. Showing neuropathy is related to increased mortality in diabetic patients—a survival analysis using an accelerated failure time model. J Clin Epidemiol. 2000;53:519–23. https://doi.org/10.1016/s0895-4356(99)00170-5.CrossRefPubMed

33.

Hsu WC, Chiu SH, Yen AF, Chen LS, Fann CY, Liao CS, Chen HH. Somatic neuropathy is an independent predictor of all-and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol. 2012;19:1192–8. https://doi.org/10.1111/j.1468-1331.2011.03659.x.CrossRefPubMed

34.

Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol. 2005;5:24–8. https://doi.org/10.1186/1471-2377-5-24.CrossRefPubMedPubMedCentral

35.

Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Ann Saudi Med. 2007;27:25–31. https://doi.org/10.4103/0256-4947.51536.CrossRefPubMedPubMedCentral

36.

Callaghan B, Feldman E. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol. 2013;74:397–403. https://doi.org/10.1002/ana.23986.CrossRefPubMed

37.

Smith AG, Singleton JR. Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complicat. 2013;27:436–42. https://doi.org/10.1016/j.jdiacomp.2013.04.003.CrossRefPubMedPubMedCentral

38.

Thomas PK, Ward JD, Watkins PJ. Diabetic neuropathy: complications of diabetes. London: Edward Arnold publications; 1982. p. 109–36.

39.

Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51–63. https://doi.org/10.1186/1741-7015-12-51.CrossRefPubMedPubMedCentral

40.

Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995;58:625–8. https://doi.org/10.1136/jnnp.58.5.625.CrossRefPubMedPubMedCentral

41.

Kluding PM, Pasnoor M, Singh R, Jernigan S, Farmer K, Rucker J, Sharma N, Wright DE. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complicat. 2012;26:424–9. https://doi.org/10.1016/j.jdiacomp.2012.05.007.CrossRefPubMedPubMedCentral

42.

Paul D, Loprinzi A, Kathy K, Hager B, Pradeep Y, Ramulu C. Physical activity, glycemic control, and diabetic peripheral neuropathy: a national sample. J Diabetes Complicat. 2014;28:17–21. https://doi.org/10.1016/j.jdiacomp.2013.08.008.CrossRef

43.

Loprinzi PD, Ramulu PY. Objectively measured physical activity and inflammatory markers among US adults with diabetes: implications for attenuating disease progression. Mayo Clin Proc. 2013;88:942–51. https://doi.org/10.1016/j.mayocp.2013.05.015.CrossRefPubMed

44.

Diabetes Control and Complication Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8. https://doi.org/10.7326/0003-4819-122-8-199504150-00001.CrossRef

45.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67. https://doi.org/10.1001/jama.290.16.2159.CrossRef

46.

Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006;29:340–4. https://doi.org/10.2337/diacare.29.02.06.dc05-1549.CrossRefPubMedPubMedCentral

47.

Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14:1–5. https://doi.org/10.1007/s11892-014-0528-7.CrossRef

48.

Dziemidok P, Szczesniak G, Kostrzewa-Zablocka E, Paprzycki P, Korzon-Burakowska A. Current glycaemic control has no impact on the advancement of diabetic neuropathy. Ann Agric Environ Med. 2012;19:742–5.PubMed

49.

Xu F, Zhao LH, Su JB, Chen T, Wang XQ, Chen JF, Wu G, Jin Y, Wang XH. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6:1–7. https://doi.org/10.1186/1758-5996-6-139.CrossRef

50.

Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) cohort. Diabetes Care. 2013;36:3208–15. https://doi.org/10.2337/dc13-0012.CrossRefPubMedPubMedCentral

51.

Kostev K, Jockwig A, Hallwachs A, Rathmann W. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and UK. Prim Care Diabetes. 2014;8:250–5. https://doi.org/10.1016/j.pcd.2014.01.011.CrossRefPubMed

52.

Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54:2179–87. https://doi.org/10.2337/diabetes.54.7.2179.CrossRefPubMed

53.

Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schönbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26:611–7. https://doi.org/10.1161/01.atv.0000201938.78044.7.CrossRefPubMed

54.

Savage S, Estacio RO, Jeffers B, Schrier RW. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. Proc Assoc Am Physicians. 1997;109:181–9.PubMed

Title: The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan
Authors: Nahla Khawaja
Jawad Abu-Shennar
Mohammed Saleh
Said S. Dahbour
Yousef S. Khader
Kamel M. Ajlouni
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Diabetology & Metabolic Syndrome / Issue 1/2018
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-018-0309-6

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Comparative effects of vitamin D and vitamin C supplementations with and without endurance physical activity on metabolic syndrome patients: a randomized controlled trial

The impact of a disease management programme for type 2 diabetes on health-related quality of life: multilevel analysis of a cluster-randomised controlled trial

The association between attitude, self-efficacy, and social support and adherence to diabetes self-care behavior

Interaction between a variant of chromosome 9p21.3 locus and diet antioxidant capacity on metabolic syndrome in Tehrani adults

Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage